Infantile Spasm (West Syndrome) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Infantile Spasm (West Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions.
Infantile Spasm also known as West Syndrome is a type of seizures and most seen in children. Observed in children up to 5 years of age and can develop into other seizures in rare cases. Sudden stiffening of arms and legs, head thrown back, commonly observed when woke up from sleep and rare in sleep. These seizures last for four to five seconds. It is a rare form of seizure that stops by the age four or five. Trauma, genetic causes, metabolic causes, are common etiological factors. Physical examination, CT scan, EEG findings, MRI are by which diagnosis done. Hormonal therapy with prednisolone, anti-seizure medications with ketogenic diet is recommended.
The Infantile Spasm (West Syndrome) drugs in development market research report provide comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Infantile Spasm (West Syndrome) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Infantile Spasm (West Syndrome) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Infantile Spasm (West Syndrome) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Infantile Spasm (West Syndrome) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Anavex Life Sciences CorpBio-Pharm Solutions Co Ltd
Cerecin Pte Ltd
Clinuvel Pharmaceuticals Ltd
Jazz Pharmaceuticals Plc
Ovid Therapeutics Inc
Shanghai Pharmaceuticals Holding Co Ltd
UCB SA
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Infantile Spasm (West Syndrome) reports